HC Wainwright set a $12.00 price target on Foamix Pharmaceuticals (NASDAQ:FOMX) in a research note published on Wednesday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Separately, Zacks Investment Research cut shares of Foamix Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, October 3rd.

Shares of Foamix Pharmaceuticals (NASDAQ:FOMX) traded down $0.02 during mid-day trading on Wednesday, hitting $5.67. 37,213 shares of the stock were exchanged, compared to its average volume of 76,390. Foamix Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $11.27.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). Foamix Pharmaceuticals had a negative net margin of 1,439.32% and a negative return on equity of 54.81%. The business had revenue of $0.90 million during the quarter, compared to analyst estimates of $0.90 million. During the same quarter in the prior year, the company posted ($0.19) EPS. The company’s quarterly revenue was down 64.6% compared to the same quarter last year. sell-side analysts forecast that Foamix Pharmaceuticals will post -1.34 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in FOMX. Wells Fargo & Company MN raised its stake in shares of Foamix Pharmaceuticals by 1,738.5% in the 3rd quarter. Wells Fargo & Company MN now owns 47,801 shares of the specialty pharmaceutical company’s stock valued at $265,000 after buying an additional 45,201 shares in the last quarter. PDT Partners LLC acquired a new stake in shares of Foamix Pharmaceuticals during the 2nd quarter worth about $304,000. Renaissance Technologies LLC acquired a new stake in shares of Foamix Pharmaceuticals during the 1st quarter worth about $307,000. UBS Asset Management Americas Inc. increased its position in shares of Foamix Pharmaceuticals by 1.6% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 106,312 shares of the specialty pharmaceutical company’s stock worth $493,000 after purchasing an additional 1,633 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Foamix Pharmaceuticals by 363.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 148,981 shares of the specialty pharmaceutical company’s stock worth $737,000 after purchasing an additional 116,861 shares in the last quarter. Institutional investors own 57.43% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.dailypolitical.com/2017/12/02/hc-wainwright-analysts-give-foamix-pharmaceuticals-fomx-a-12-00-price-target.html.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.